Skin melanoma in a rheumatoid arthritis patient treated with infliximab
More details
Hide details
Online publication date: 2009-06-10
Reumatologia 2009;47(2):98–100
We present a case of skin melanoma in a 53-year-old patient with rheumatoid arthritis (RA) treated with infliximab and methotrexate. After 12 months of therapy during a routine examination before infusion of infliximab, the enlarging pigmented naevus on the skin of the right arm was prophylactically removed. Histopathological evaluation and immunohistochemistry led to the diagnosis of skin melanoma. We suggest that systematic control of the pigmented naevus during anti-TNF therapy should be strongly recommended.
Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006; 154: 880-884. .
Lipsky PE, Desiree MFM, van der Heijde MD, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-1602. .
Geborek P, Bladstrom A, Turesson C, et al. Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703. .
Mellemkjaer L, Line MS, Gridly G. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753-1757. .
Bucher C, Degen L, Dirnhofer S, et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 2005; 54: 732-733. .
Bakland G, Nossent H. Acute myelogenous leukemia following etanercept therapy. Rheumatology 2003; 42: 900-901. .
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid Arthritis and the risk of serious infections and malignancies. JAMA 2006; 295: 2275-2285. .
Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicenter matched pair study. Gut 2006; 55: 228-233. .
Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-2135. .
Askling J, Fored CM, Brand L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-1430. .
Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneus sqamosus cell carcinoma In patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005; 141: 861-864. .
Hrycaj P, Korczowska I, Łącki JK. Severe Parkinson’s disease in rheumatoid arthritis patient treatment with infliximab. Rheumatology 2003; 42: 702-703.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.